TTNP - Titan Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.336
-0.042 (-11.07%)
As of 12:52PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.378
Open0.400
Bid0.341 x 1000
Ask0.345 x 1200
Day's Range0.322 - 0.400
52 Week Range0.172 - 2.850
Volume12,482,366
Avg. Volume3,564,830
Market Cap9.109M
Beta (3Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-0.534
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.98
Trade prices are not sourced from all markets
  • ACCESSWIRE5 hours ago

    Today's Research Reports on Trending Tickers: Titan Pharmaceuticals and Amarin Corporation

    NEW YORK, NY / ACCESSWIRE / October 22, 2018 / U.S. equities finished mostly lower on Friday as earlier gains due to upbeat corporate earnings were hamstrung by a weakness in housing sales. According to ...

  • ACCESSWIRE7 days ago

    Titan Pharmaceuticals Moving Forward with its ProNeura™ Technology, Analysts Review

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer
    PR Newswire20 days ago

    Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a commercial stage company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced the appointment of Dane D. Hallberg to the newly created position of Executive Vice President and Chief Commercial Officer, effective immediately. Mr. Hallberg will be responsible for leading all of the company's commercial activities. "Dane brings to Titan important experience and depth of knowledge in sales and marketing, product launch and market access as we relaunch Probuphine and work to maximize this commercial opportunity," said Titan's President and CEO, Sunil Bhonsle.

  • Titan Pharmaceuticals Prices $9,500,000 Public Offering
    PR Newswirelast month

    Titan Pharmaceuticals Prices $9,500,000 Public Offering

    SOUTH SAN FRANCISCO, Calif., Sept. 20, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) ("Titan" or the "Company"), a commercial stage company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology,  today announced the pricing of an underwritten public offering with expected total gross proceeds of $9,500,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) Class A Units consisting of 5,100,000 shares of our Common Stock and Warrants to purchase 5,100,000 shares of Common Stock, and (ii) Class B Units consisting of 8,225 shares of our Series A Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 32,900,000 shares of Common Stock, and Warrants exercisable for the number of shares of Common Stock into which the shares of Series A Convertible Preferred Stock are convertible.

  • Who Owns Titan Pharmaceuticals Inc (NASDAQ:TTNP)?
    Simply Wall St.last month

    Who Owns Titan Pharmaceuticals Inc (NASDAQ:TTNP)?

    If you want to know who really controls Titan Pharmaceuticals Inc (NASDAQ:TTNP), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions asRead More...

  • Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse
    PR Newswirelast month

    Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse

    SOUTH SAN FRANCISCO, Calif., Sept. 10, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has been awarded a two year grant of approximately $6.7 million from the National Institutes of Health's National Institute on Drug Abuse (NIDA) for the development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification.  The grant provides approximately $2.7 million for the project from now through August 31, 2019, with the balance to be funded over the subsequent year, subject to satisfactory project progress, fund availability and certain other conditions. "NIDA previously provided funds for an important Phase 3 trial of our approved product, Probuphine®, and we are grateful for this additional vote of confidence in our ProNeura technology as well as our ability to execute on another program for the treatment of opioid addiction," said Titan's Chief Scientific Officer and Principal Investigator of the project, Dr. Kate DeVarney.

  • Associated Press2 months ago

    Titan Pharmaceuticals: 2Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 4 cents per share. The specialty pharmaceutical company posted revenue of $2.7 million in the period. In the final minutes of trading on Tuesday, the ...

  • PR Newswire2 months ago

    Titan Pharmaceuticals Reports Second Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing ...

  • Titan Announces Amendment To Agreement With Molteni
    PR Newswire3 months ago

    Titan Announces Amendment To Agreement With Molteni

    SOUTH SAN FRANCISCO, Calif., Aug. 3, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) announced today that it has entered into an amendment (the "Amendment") of the previously announced definitive asset purchase, supply and support agreement (the "Purchase Agreement") with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni acquired the European intellectual property related to Probuphine®. Under the Amendment, Molteni will make an immediate payment to Titan of €950,000 (approx. $1.1 million), and has committed to make a convertible loan to Titan of €550,000 (approx. $0.6 million) in mid-September subject to Titan's submission, in accordance with the Amendment, of a response to questions posed by the European Medicines Agency (EMA), in exchange for the elimination of an aggregate of €2.0 million (approx. $2.3 million) of regulatory milestones provided for in the Purchase Agreement, which would be payable potentially in 2019 at the earliest.

  • Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program
    PR Newswire4 months ago

    Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program

    SAN FRANCISCO , July 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ ...

  • Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence
    PR Newswire5 months ago

    Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence

    SOUTH SAN FRANCISCO, Calif. and PLYMOUTH MEETING, Pa., May 30, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada. Under the terms of the termination agreement, Titan will regain all rights to the commercialization and clinical development of Probuphine in the U.S. and Canada. Braeburn has paid Titan $1 million and will provide assistance to Titan through December 28, 2018 to enable a smooth transition and ensure that patients and their doctors will continue to have support and access to this treatment.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of TTNP earnings conference call or presentation 16-May-18 8:15pm GMT

    Q1 2018 Titan Pharmaceuticals Inc Earnings Call

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 15) Inspire Medical Systems Inc (NYSE: INSP ) Aptevo Therapeutics ...

  • Associated Press5 months ago

    Titan Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the San Francisco-based company said it had a loss of 12 cents. The specialty pharmaceutical company posted revenue of $1.1 million in the period. In the final minutes of trading ...

  • Titan Pharmaceuticals Reports First Quarter 2018 Financial Results
    PR Newswire5 months ago

    Titan Pharmaceuticals Reports First Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif. , May 15, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing ...

  • Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board
    PR Newswire5 months ago

    Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board

    SOUTH SAN FRANCISCO, Calif. , May 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing ...

  • Titan Pharmaceuticals To Report First Quarter 2018 Financial Results On May 15, 2018
    PR Newswire5 months ago

    Titan Pharmaceuticals To Report First Quarter 2018 Financial Results On May 15, 2018

    Management Team to Host Conference Call the Following Day - May 16, 2018 - at 4:15 p.m. ET / 1:15 p.m. PT SOUTH SAN FRANCISCO, Calif. , May 8, 2018 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), ...

  • Zacks Small Cap Research6 months ago

    TTNP: Molteni Investment Relieves the Pressure

    The update caps a year with Probuphine revenues well below expectations. To address the weak sales by partner Braeburn, Titan began discussions to return commercialization rights. Due to the slow ramp of sales from Probuphine in the summer of 2017, Titan secured a debt facility from Horizon Technology Finance in July to fund the development programs in the pipeline.

  • ACCESSWIRE6 months ago

    Wired News – Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual Meeting

    Stock Monitor: Titan Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Conatus Pharma Inc. (NASDAQ: CNAT ). If you ...

  • InvestorPlace7 months ago

    3 Stocks to Watch on Tuesday: Atlas Financial Holdings Inc (AFH), Eastside Distilling Inc (EAST) and Titan Pharmaceuticals, Inc. (TTNP)

    U.S. stocks plummeted Monday as the tech industry was hit hard and Amazon.com, Inc. (NASDAQ:AMZN) experienced a selloff, falling 5%. The S&P 500 Index fell 2.2%, the Dow Jones Industrial Average slid 1.9% and the Nasdaq Composite fell 2.7%.

  • ACCESSWIRE7 months ago

    Titan Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 2, 2018 at 4:15 PM Eastern ...

  • Associated Press7 months ago

    Titan Pharmaceuticals reports 4Q loss

    The San Francisco-based company said it had a loss of 17 cents per share. The specialty pharmaceutical company posted revenue of $58,000 in the period. For the year, the company reported a loss of $14.3 ...

  • Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results
    PR Newswire7 months ago

    Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

    Titan Management Team to Host Conference Call April 2 at 4:15 p.m. EDT / 1:15 p.m. PDT SOUTH SAN FRANCISCO, Calif. , April 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company ...

  • Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results
    PR Newswire7 months ago

    Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 26, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced that it will host a live conference call at 4:15 p.m. ET / 1:15 p.m. PT on Monday, April 2, 2018 to discuss the company's financial results as of December 31, 2017. The call can also be accessed by dialing 1-855-940-9476 (or 1-412-317-5223 from outside the U.S.) five minutes prior to the start time, and asking to be joined into the Titan Pharmaceuticals, Inc. call. An audio recording of the call will also be archived on the Titan website.